Loading
Cell therapies built from a rare T-cell type that recognises stressed cancer cells without needing tissue matching, making them candidates for off-the-shelf products.
Gamma-delta T cells recognise stress ligands and phosphoantigens on tumour cells independently of HLA, so donor cells can be given without matching and without causing graft-versus-host disease. Companies expand the Vδ1 or Vδ2 subsets from healthy donors, sometimes adding a CAR, and early trials in leukaemia, lymphoma and solid tumours are under way. Persistence after infusion and manufacturing scale are the main hurdles.
Donor gamma-delta T cells are expanded ex vivo with phosphoantigens or cytokines, optionally engineered with a chimeric antigen receptor, and infused as an allogeneic product.
Query for this technology: (TITLE:"Gamma-delta T cell therapy" OR ABSTRACT:"Gamma-delta T cell therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gamma-delta T cell therapy, not a curated reading list.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.